LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Liquid Biopsy Enables Early Diagnosis of Leptomeningeal Disease in Diffuse Midline Gliomas

By LabMedica International staff writers
Posted on 28 Jan 2025
Image: The study succeeded in early diagnosis of leptomeningeal disease in diffuse midline gliomas by liquid biopsy (Photo courtesy of Niigata University)
Image: The study succeeded in early diagnosis of leptomeningeal disease in diffuse midline gliomas by liquid biopsy (Photo courtesy of Niigata University)

Leptomeningeal disease (LMD) in diffuse midline gliomas (DMGs) can lead to debilitating symptoms such as intense pain, urinary incontinence, and tetraparesis, with limited treatment options available. A new study has found that detecting H3F3A K27M-mutant droplets in cerebrospinal fluid (CSF) circulating tumor deoxyribonucleic acid (ctDNA) could serve as a biomarker for identifying LMD in DMGs.

In the study, researchers from Niigata University’s Brain Research Institute (Niigata, Japan) collected 25 CSF samples from 22 DMG patients. The team utilized droplet digital PCR, a highly sensitive PCR technique, to detect trace amounts of ctDNA from the CSF of these patients. They successfully diagnosed LMD in DMGs by identifying H3K27M-mutant droplets in the ctDNA from the CSF samples. The findings, published in Pediatric Blood & Cancer, show that in two patients, LMD was diagnosed earlier than through traditional methods like MRI and CSF cytology. In one case, early diagnosis of LMD followed by aggressive interventions, including surgery, radiation, and intrathecal chemotherapy, resulted in long-term survival. The study demonstrates that detecting H3F3A K27M-mutant droplets in CSF ctDNA is not only diagnostic for LMD but also more sensitive than traditional diagnostic techniques, such as CSF cytology and MR imaging.

“We found that detecting circulating tumor DNA in the cerebrospinal fluid of diffuse midline glioma patients was more difficult than other brain tumor patients such primary central nervous system lymphoma and glioblastoma,” said Dr. Manabu Natsumeda, who led the research team. “However, when we were able to detect mutant tumor DNA, often the tumor had already spread to the cerebrospinal fluid, causing leptomeningeal disease. We think that early diagnosis and treatment of leptomeningeal disease in diffuse midline gliomas can improve survival.”

Related Links:
Niigata University Brain Research Institute

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Gold Member
Hybrid Pipette
SWITCH

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more